Venture financing remained active this week with large rounds and strategic seed closes across geographies. Chinese innovators D3 Bio and Sanegene each secured rounds exceeding $100 million, underscoring sustained appetite for domestic genomics, therapeutics and platform plays in China’s private markets. These raises were announced alongside mid‑stage venture activity in other regions. In Europe, Disco Pharmaceuticals closed a €36 million seed round to advance its surfaceome discovery platform into formal preclinical development. The financing will accelerate target validation and IND‑enabling work, marking a notable vote of confidence for surfaceome‑focused target discovery. The deals reflect both regional capital depth in China and targeted seed interest in modality platforms in Europe, with implications for partnering, talent recruitment and translational timelines as startups move from discovery to candidate selection.